BCL2 and prostate cancer: Accordingly, these results suggest that the TGF-β/acetylated KLF5/BCL2 signaling axis mediates DTX resistance in prostate cancer and that targeting this signaling axis might be a novel therapeutic approach for the treatment of chemo-resistant prostate cancer.